skincaremanual.org

PLX-PAD therapy improves quality of life in CLI patients

March 12, 2017

-Immunological profiles demonstrated a rise in anti-inflammatory and angiogenic protein secretion post-dosing suggesting PLX-PAD cells function to deliver appropriate therapeutics proteins in response to the ischemic, inflammatory process of CLI.

Efficacy Parameters:

-Across all doses, 13 patients (62%) demonstrated an improvement in the ankle-brachial index (ABI), a measure of blood flow. Eleven patients receiving the intermediate dose demonstrated a statistically significant improvement from baseline>

-Across all doses, 13 patients (62%) demonstrated an improvement in the Transcutaneous Oxygen Pressure (TcPO2), a measure of tissue oxygenation. This improvement was statistically significant in the European study where the distribution of injections was higher>

-Across all doses, 17 patients (81%) demonstrated an improvement in ABI, TBI or TcPO2.

-Across all doses, 17 patients (81%) demonstrated a statistically significant improvement from baseline in the King's College Score for Quality of Life (QoL) assessment (P< 0.001). Eleven patients receiving the intermediate doses demonstrated the best improvement from baseline in the QoL score (P< 0.001).

-Across all doses, 15 patients (71%) demonstrated an improvement from baseline in the reduction of pain as measured by using the VAS. This improvement was statistically significant in the European study where the distribution of injections was higher>

"The results of these trials provide a strong indication of the potential success of commercializing PLX-PAD," said Zami Aberman, President, Chairman and CEO of Pluristem. "We have proven our PLX-PAD cells are safe and well tolerated when given intramuscularly as an allogeneic, "off-the-shelf" product that can be given without the need for matching between the donor and the patient. Additionally, Pluristem has been able to choose the appropriate dose of PLX-PAD to move commercialization of the product forward."

Source : Pluristem Therapeutics